论文部分内容阅读
目的 为了简化紫杉醇静脉化疗预处理方案 ,提高工作效率。方法 化疗方案 :18例次均采用紫杉醇+顺铂方案 ;紫杉醇预处理方案 :于应用紫杉醇前 30分钟给予地塞米松 2 0 m g静脉点滴 ,同时给予西米替丁 30 0 mg静脉推注 ,苯海拉明 5 0 mg肌肉注射。结果 1例膀胱浸润性移行细胞癌达到 CR,2例肺鳞状细胞癌达到 PR,1例肺腺癌 PD,1例鼻咽低分化鳞癌 PD,2例乳腺癌 PD;1例乳腺癌患者是术后辅助化疗 ,不能评价疗效。毒副反应 :(1)骨髓抑制 : 度 2例次 , 度 1例次 ,发生率 16 %。 (2 )脱发 :有 16例次出现 ,发生率 89%。 (3)关节和肌肉酸痛 :有2例次发生 ,发生率 11%。 (4)周围神经病变 :2例次出现肢端麻木。全组未出现 1例过敏反应。结论 建议在给予紫杉醇静脉化疗时 ,从第三周期起常规采用简化预处理方案 ,这样可简化患者服药次数 ,简化工作程序 ,提高工作效率
Objective To simplify the paclitaxel intravenous chemotherapy preconditioning program to improve work efficiency. Chemotherapy regimens: 18 cases were treated with paclitaxel + cisplatin regimen; paclitaxel pretreatment program: 30 minutes before the application of paclitaxel dexamethasone 20 mg intravenous infusion of cimetidine 30 0 mg simultaneously, benzene Hylamine 50 mg intramuscularly. Results One case of bladder invasive transitional cell carcinoma achieved CR, two cases of lung squamous cell carcinoma reached PR, one case of lung adenocarcinoma PD, one case of nasopharyngeal poorly differentiated squamous cell carcinoma PD, two cases of breast cancer PD; one case of breast cancer Postoperative adjuvant chemotherapy, can not evaluate the efficacy. Toxicity and side effects: (1) Myelosuppression: degree 2 cases, degree 1 case, the incidence of 16%. (2) hair loss: 16 cases occurred, the incidence of 89%. (3) joint and muscle soreness: 2 cases occurred, the incidence of 11%. (4) Peripheral neuropathy: 2 cases of extremity numbness. The whole group did not appear in 1 case of allergic reaction. CONCLUSIONS: Paclitaxel intravenous chemotherapy is recommended as a simplified preconditioning regimen from the third cycle, which simplifies patient administration, simplifies procedures and increases productivity